NOV 01, 2019 9:28 PM PDT

myTAIHEART Blood Test and Biopsy of Heart Transplant Recipients

WRITTEN BY: Nupur Srivastava

Transplant rejection is a process where the immune system of the patient consider the donor's organ as foreign and rejects them. The patient's immune system detects the antigens on the cells of the organ as different or not "matched." 

Transplant rejection is the critical determinant of patient outcome, and routine monitoring is necessary to detect rejection. Tissue biopsy is the standard monitoring tracker for organ rejection status. Tissue biopsies present risks to the patients and are painful, subject to sampling error, and expensive for the patient and healthcare system.

The researchers identified an effective and sensitive method of myTAIHEART tests for monitoring organ status rejection. The myTAIHEART® quantitatively genotype cell-free DNA (cfDNA) in the patient’s plasma. The test directly measures organ injury through the identification and quantification of donor-specific cell-free DNA released from damaged cells in the patient’s blood. 

What is myTAIHEART®?

  • myTAIHEART®  test is a laboratory-developed test to analyze the release of donor-specific cell-free DNA in the blood of heart transplant patients before and after receiving heart biopsies.
  • It is available for use in post-transplant monitoring of pediatric (2 months of age or older) and adult heart transplant patients (at least 1-week post-transplant ≥7 days). 
  • The myTAIHEART® test is performed with a small blood sample and does not require tissue biopsy.
  • The test helps in identifying heart transplant recipients who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.

The researchers confirmed the effectiveness of myTAIHEART® test by conducting a clinical study on the "Effect of endomyocardial biopsy on levels of donor-specific cell-free DNA." The study is published jointly by Steven Zangwill, MD, Karl Stamm, Ph.D., Mats Hidestrand, Ph.D., Aoy Tomita-Mitchell, Ph.D., and Michael Mitchell, MD. in the October 2019 issue of The Journal of Heart and Lung Transplantation.

The clinical study included 20 paired samples. The study analysis indicated that the standard biopsy causes significant injury to a transplanted heart. myTAIHEART® test, developed by TAI Diagnostics, Wauwatosa, WI, determined the quantities of total and DF (%) cfDNA levels. 

How does myTAIHEART® test work?

myTAIHEART® distinguishes “donor-specific” cfDNA originating from the engrafted heart versus “self-specific” cfDNA originating from the recipient’s native cells. The myTAIHEARTtest reports the ratio of donor-specific cfDNA to total cfDNA as the donor fraction (%) (DF). DF serves as a marker of cardiac injury in transplant patients receiving heart biopsies.

  • The patients with low donor fractions indicate less damage to the transplanted heart and a lower risk for rejection.
  • The patients with increased donor fractions indicate more damage to the transplanted heart and an increased risk for rejection.

The myTAIHEART® test is exquisitely sensitive to injury to the donor organ, said Dr. Aoy Mitchell, co-author, and co-inventor of the test.

Source: JHLT, myTAIHEART

About the Author
You May Also Like
AUG 03, 2020
Cancer
Improving Diagnostics in Breast Cancer
AUG 03, 2020
Improving Diagnostics in Breast Cancer
Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a ...
AUG 06, 2020
Clinical & Molecular DX
Gut Feeling: Spotting the Early Signs of Gastric Cancer
AUG 06, 2020
Gut Feeling: Spotting the Early Signs of Gastric Cancer
In a study published in Science Advances, scientists propose a new method for diagnosing gastric cancer, the third leadi ...
OCT 06, 2020
Clinical & Molecular DX
Radioactive Tracer Shines the Floodlights on Inflammation
OCT 06, 2020
Radioactive Tracer Shines the Floodlights on Inflammation
A patient checks into the hospital with difficulty breathing. Is inflammation to blame? How can physicians visualize are ...
NOV 03, 2020
Genetics & Genomics
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
NOV 03, 2020
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
Genetic sequencing technologies have rapidly advanced, reducing the time required to sequence the entire human genome fr ...
NOV 16, 2020
Clinical & Molecular DX
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
NOV 16, 2020
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
The demand for diagnostic technologies to track COVID-19 infections and control community spread of the disease has only ...
NOV 26, 2020
Clinical & Molecular DX
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
NOV 26, 2020
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
New research has revealed that exposure to radiation from diagnostic procedures such as X-rays could contribute to an el ...
Loading Comments...